Cargando…

Monoamine-oxidase Type B Inhibitors and Cognitive Functions in Parkinson’s Disease: Beyond the Primary Mechanism of Action

Symptoms of cognitive impairment are rather common since the early stage of Parkinson’s disease (PD); they aggravate with disease progression and may lead to dementia in a significant proportion of cases. Worsening of cognitive symptoms in PD patients depends on the progression of subcortical dopami...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rinaldi, Domiziana, Alborghetti, Marika, Bianchini, Edoardo, Sforza, Michela, Galli, Silvia, Pontieri, Francesco E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2023
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286595/ https://www.ncbi.nlm.nih.gov/pubmed/36065929 http://dx.doi.org/10.2174/1570159X20666220905102144

Ejemplares similares

Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings
por: Alborghetti, Marika, et al.
Publicado: (2023)

Feasibility, Safety, and Effectiveness of Telerehabilitation in Mild-to-Moderate Parkinson's Disease
por: Bianchini, Edoardo, et al.
Publicado: (2022)

Age at Onset Influences Progression of Motor and Non-Motor Symptoms during the Early Stage of Parkinson’s Disease: A Monocentric Retrospective Study
por: De Carolis, Lanfranco, et al.
Publicado: (2023)

Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson’s Disease: From Bench to Bedside
por: Alborghetti, Marika, et al.
Publicado: (2019)

Step-Counting Accuracy of a Commercial Smartwatch in Mild-to-Moderate PD Patients and Effect of Spatiotemporal Gait Parameters, Laterality of Symptoms, Pharmacological State, and Clinical Variables
por: Bianchini, Edoardo, et al.
Publicado: (2022)

The impact of cerebral vasomotor reactivity on cerebrovascular diseases and cognitive impairment
por: Sforza, Michela, et al.
Publicado: (2022)

Four Days Are Enough to Provide a Reliable Daily Step Count in Mild to Moderate Parkinson’s Disease through a Commercial Smartwatch
por: Bianchini, Edoardo, et al.
Publicado: (2023)

Cognitive dual-task cost depends on the complexity of the cognitive task, but not on age and disease
por: Bianchini, Edoardo, et al.
Publicado: (2022)

Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors
por: Chiuccariello, Lina, et al.
Publicado: (2015)

ABUSE OF MONOAMINE OXIDASE INHIBITORS
por: Ananth, Jambur, et al.
Publicado: (1995)

Monoamine Oxidase B in Renal Cell Carcinoma
por: Hodorová, Ingrid, et al.
Publicado: (2018)

9-Methyl-β-carboline inhibits monoamine oxidase activity and stimulates the expression of neurotrophic factors by astrocytes
por: Keller, Sebastian, et al.
Publicado: (2020)

Drug Choices and Advancements for Managing Depression in Parkinson's Disease
por: Assogna, Francesca, et al.
Publicado: (2020)

Neurophysiological assessment of juvenile parkinsonism due to primary monoamine neurotransmitter disorders
por: Passaretti, Massimiliano, et al.
Publicado: (2022)

Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
por: Tan, Yu-Yan, et al.
Publicado: (2022)

Neuroprotective Function of Rasagiline and Selegiline, Inhibitors of Type B Monoamine Oxidase, and Role of Monoamine Oxidases in Synucleinopathies
por: Naoi, Makoto, et al.
Publicado: (2022)

Amphetamine Derivatives as Monoamine Oxidase Inhibitors
por: Reyes-Parada, Miguel, et al.
Publicado: (2020)

Parameters for Irreversible Inactivation of Monoamine Oxidase
por: Ramsay, Rona R., et al.
Publicado: (2020)

Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson’s disease
por: Robottom, Bradley J
Publicado: (2011)

Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
por: Teo, Kay Cheong, et al.
Publicado: (2013)

Monoamine Oxidase Inhibitors: A Review of Their Anti-Inflammatory Therapeutic Potential and Mechanisms of Action
por: Ostadkarampour, Mahyar, et al.
Publicado: (2021)

3-Coumaranone derivatives as inhibitors of monoamine oxidase
por: Van Dyk, Adriaan S, et al.
Publicado: (2015)

Cardiac monoamine oxidases: at the heart of mitochondrial dysfunction
por: Mialet-Perez, Jeanne, et al.
Publicado: (2020)

Multiscale Modeling of Two-Photon Probes for Parkinson’s Diagnostics Based on Monoamine Oxidase B Biomarker
por: Murugan, N. Arul, et al.
Publicado: (2020)

Monoamine Oxidase-A Inhibition and Associated Antioxidant Activity in Plant Extracts with Potential Antidepressant Actions
por: Herraiz, Tomás, et al.
Publicado: (2018)

Postural Dynamics Are Associated With Cognitive Decline in Parkinson's Disease
por: Pantall, Annette, et al.
Publicado: (2018)

Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint
por: Alborghetti, Marika, et al.
Publicado: (2022)

Age-Related Behavioral Phenotype of an Astrocytic Monoamine Oxidase-B Transgenic Mouse Model of Parkinson’s Disease
por: Lieu, Christopher A., et al.
Publicado: (2013)

Beyond Dopamine: GABA, Glutamate, and the Axial Symptoms of Parkinson Disease
por: O'Gorman Tuura, Ruth L., et al.
Publicado: (2018)

Smoking Related Diseases: The Central Role of Monoamine Oxidase
por: Rendu, Francine, et al.
Publicado: (2011)

Androgen receptor and monoamine oxidase polymorphism in wild bonobos
por: Garai, Cintia, et al.
Publicado: (2014)

Inhibition of Monoamine Oxidase by Stilbenes from Rheum palmatum
por: Wei, Bo, et al.
Publicado: (2016)

Mitochondrial Monoamine Oxidase: Another Player in Pulmonary Hypertension?
por: Sommer, Natascha, et al.
Publicado: (2021)

Recent advances on the role of monoamine oxidases in cardiac pathophysiology
por: Kaludercic, Nina, et al.
Publicado: (2023)

Examination of betahistine bioavailability in combination with the monoamine oxidase B inhibitor, selegiline, in humans—a non-randomized, single-sequence, two-period titration, open label single-center phase 1 study (PK-BeST)
por: Strupp, Michael, et al.
Publicado: (2023)

Effect of Alkaloids Isolated from Phyllodium pulchellum on Monoamine Levels and Monoamine Oxidase Activity in Rat Brain
por: Cai, Lu, et al.
Publicado: (2016)

Boxing for Parkinson's Disease: Has Implementation Accelerated Beyond Current Evidence?
por: Morris, Meg E., et al.
Publicado: (2019)

Methylxanthines Inhibit Primary Amine Oxidase and Monoamine Oxidase Activities of Human Adipose Tissue
por: Haj Ahmed, Wiem, et al.
Publicado: (2020)

Action Observation for Neurorehabilitation in Apraxia
por: Pazzaglia, Mariella, et al.
Publicado: (2019)

Tranylcypromine specificity for monoamine oxidase is limited by promiscuous protein labelling and lysosomal trapping
por: Drechsel, Jonas, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_735rlhg642ibrn0jnj9anq5mm0